From Yahoo Finance: 2025-06-12 18:33:00

Viking Therapeutics (VKTX) saw a 5.69% rise in share prices to $29.14 on Tuesday, driven by anticipation of updates from global healthcare conferences. The company gained momentum after Pfizer scrapped its obesity drug, leaving VKTX’s VK2735 candidate in a favorable position. VKTX ranks 8th on the list of top-performing companies.

Investors are eagerly awaiting news from the 46th Annual Goldman Sachs Global Healthcare Conference and the Scotiabank Third Annual Healthcare Canadian Investor Day, where Viking Therapeutics (VKTX) is set to participate. VKTX’s growth prospects are bolstered by Pfizer’s exit from the obesity drug market, providing a promising outlook for the company.

Viking Therapeutics (VKTX) is capitalizing on Pfizer’s exit from the obesity drug race, positioning itself favorably with the development of VK2735. Despite its potential, VKTX faces competition from other AI stocks that offer higher returns and lower risks. Investors seeking AI investments should consider alternatives for better opportunities.

Read more: Viking Therapeutics (VKTX) Rises on Expected Developments